Diagnostics Partnering Terms and Agreements -





Published: July 2014 | Edition: 7 | Pages: 2,766 (including appendices)

The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms and big pharma and big biotech activities.

                             

Chapter 3 provides a review of the leading diagnostics deals since 2009. Deals are listed by headline value and signed by big pharm. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies that have announced diagnsotic deals, with a brief summary followed by a comprehensive listing of diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies that have announced diagnsotic deals, where diagnostic deals are announced with a brief summary, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by cpmpany A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2009. The chapter is organized by specific diagnostics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in diagnostics partnering and dealmaking since 2009.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of diagnostics technologies and products.

 

Report scope 

 

Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide.

 

Diagnostics Partnering Terms and Agreements includes:

 

  • Trends in diagnostic dealmaking in the biopharma industry since 2009
  • Analysis of diagnostic deal structure
  • Case studies of real-life diagnostic deals
  • Access to over 3,700 diagnostic deals
  • The leading diagnostic deals by value since 2009
  • Most active diagnostic dealmakers since 2009
  • The leading diagnostic partnering resources

 

In Diagnostics Partnering Terms and Agreements , the available contracts are listed by:

 

  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via Weblink to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Diagnostics Partnering Terms and Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of diagnostic deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of diagnostic agreements with numerous real life case studies
  • Comprehensive access to over 3,700 diagnostic deals entered into by the world’s biopharma companies, together with contract documents if available
  • Detailed access to actual diagnostic contracts enter into by the leading fifty big pharma and big biotech companies
  • Identify leading diagnostics deals by value since 2009
  • Identify the most active diagnostics dealmakers since 2009
  • Insight into the terms included in a diagnostic agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Executive Summary 

Chapter 1 – Introduction 

Chapter 2 – Trends in diagnostic dealmaking 

2.1. Introduction

2.2. Diagnostic partnering over the years

2.3. Most active diagnostic dealmakers

2.4. Big pharma diagnostic dealmaking activity

2.5. Big biotech diagnostic dealmaking activity

2.6. Diagnostics partnering by deal type

2.7. Diagnostics partnering by stage of development

2.8. Diagnostics partnering by disease type

2.9. Diagnostics partnering by specific technology type

2.10. Average deal terms for diagnostics partnering

2.10.1 Diagnostic partnering headline values

2.10.2 Diagnostic deal upfront payments

2.10.3 Diagnostic deal milestone payments

2.10.4 Diagnostic royalty rates

2.11. The anatomy of diagnostic partnering

2.11.1. The anatomy of a diagnostic deal

2.11.1.a. Case study 1: TrovaGene – Columbia University – December 2011

2.11.1.b. Case study 2: Neogenomics – Health Discovery – January 2012

2.11.1.c. Case study 3: Salix Pharmaceuticals – Photocure – 2010

 

Chapter 3 – Leading diagnostic deals 

3.1. Introduction

3.2. Top diagnostic deals by value

3.3. Top diagnostic deals involving big pharma

 

Chapter 4 – Big pharma diagnostic deals 

4.1. Introduction

4.2. How to use big pharma diagnostic partnering deals

4.3. Big pharma diagnostic partnering company profiles

Abbott

Actavis

Amgen

Astellas

AstraZeneca

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Chugai Pharmaceutical

Daiichi Sankyo

Eisai

Eli Lilly

Fresenius

Gilead Sciences

GlaxoSmithKline

Grifols

Hospira

Johnson & Johnson

Lundbeck

Menarini

Merck & Co

Merck KGaA

Mylan

Novartis

Pfizer

Purdue

Roche

Sanofi

Servier

Shionogi

Takeda

Teva

UCB

 

Chapter 5 – Big biotech diagnostics deals 

 

5.1. Introduction

5.2. How to use big biotech partnering deals

5.3. Big biotech diagnostic partnering company profiles

Array Biopharma

Biocon

BioMarin Pharmaceuticals

Elan

Enzo Biochem

Genmab

Gilead Sciences

Ipsen

Isis Pharmaceuticals

Morphosys

Onyx Pharmaceuticals

Seattle Genetics

Swedish Orphan Biovitrum

 

Chapter 6 – Diagnostics contracts dealmaking directory 

 

6.1. Introduction

6.2. By Company A-Z

Abaxis

Abbott Laboratories

Accuray

Achaogen

Actavis (acquired by Watson)

Acusphere

ADMA Biologics

Aegea Biotechnologies

Alnylam Pharmaceuticals

Alseres Pharmaceuticals

Altair Nanotechnologies

Amarantus BioSciences

Ambit Biosciences

AMDL Diagnostics

AmpliPhi Biosciences

Amway Global

ARK Diagnostics

Arno Therapeutics

Arrayit

Arrayit Diagnostics

AspenBio Pharma

Asuragen

Atossa Genetics

Audeo Oncology

Axial Biotech

Bayer Schering Pharma

Beckman Coulter

Beijing C&D

BG Medicine

Bio-Imaging Technologies

Bio-Matrix Scientific

Biocept

BioClinica

Biofield

Biogen Idec

Biotage

BlueWave Healthcare Consultants

Caliper Life Sciences

Celera

Celladon

Cilag AG

Clarient

Columbia University

CombiMatrix

Corgenix Medical

CorMedix

Cryolife

Cypress Bioscience

CytoCore

Cytokinetics

Dana-Farber Cancer Institute

DeCODE Genetics

Dehaier Medical Systems

Devicor Medical Products

DiagnoCure

Diaxonhit

Dr Faupel

Echo Therapeutics

ELITech

EMD Millipore

Ensisheim Partners

Entest BioMedical

EPIX Pharmaceuticals

Esaote

Exact Sciences

Fairview Health System

Fluidigm

Foundation Medicine

Future Diagnostics

Galmed Pharmaceuticals

GE Healthcare

Gen-Probe

General Electric (GE)

Genoptix

Genzyme

Genzyme Genetics

GlaxoSmithKline

GlycArt

Grifols

Guangdong Prosper Channel Medicine Company

Guided Therapeutics

Handok Pharmaceuticals

Hansen Medical

Health Diagnostic Laboratory

Health Discovery

Hologic

HyperGenomics

Hypertension Diagnostics

Illumina

ImmuMetrix

ImmunoCellular Therapeutics

InoHealth Products

Inolife Technologies

Interleukin Genetics

Inverness Medical Innovations

Inverness Medical Switzerland

Invivis Pharmaceuticals

Ipsogen

ISIS Innovation

Isis Pharmaceuticals

IsoRay

KineMed

Konica Minolta

Laboratory Corporation of America

Lantheus Medical Imaging

Life Technologies Corporation

Lifeloc Technologies

Luna Innovations

Luna Technologies

Mabtech

Manhattan Scientifics

Marina Biotech

Matsuura

Max-Planck

Mayo Clinic

MDRNA

MDS Nordion

Memory Dx

Merck and Co

Merial

MicroCoat Biotechnologie

Misonix

Munich Leukemia Laboratory

Neogenomics

Neoprobe

Norgine

Novartis

Novartis Vaccines and Diagnostics

Novel Laboratories

Olympus

Optherion

OraSure Technologies

Oxford Immunotec

Pacific Biosciences

PerkinElmer

Perugia University

Photocure ASA

Prometheus Laboratories

Psynova Neurotech

PuriCore

Quest Diagnostics

Quotient Biodiagnostics

Regulus Therapeutics

Response Genetics

RiboTask

Riken Genesis

Roche

Rosetta Genomics

Rules-Based Medicine

Rutgers University

Salix Pharmaceuticals

Scientific Nanomedicine

Senior Scientific

Sequenom

Shanghai Fosun Long March Medical Science

Shiva Biomedical

Siemens

Siemens Healthcare Diagnostics

Singulex

Skyline Diagnostics

SonoSite

Stanford University

Starch Medical

Statens Serum Institute

Stem Cell Sciences

Stemcell Technologies

StemCells

Stemline Therapeutics

STRATEC Biomedical Systems AG

SurgiVision

Tarom Applied Technologies

Techniscan

The Regents of the University of California

Third Wave Technologies

Transgenomic

TrovaGene

TTP Group

Universal Biosensors

University of Cambridge

University of Minnesota

University of Pittsburgh

US Army

USHIFU

ValiPharma

Vaso Diagnostics

Vasomedical

Veracyte

Verastem

Virovek

VolitionRX

Whitehead Institute

XDx

Xenomics

Zora Biosciences

6.3. By stage of development

Discovery

Marketed

Phase I

Phase II

Phase III

Regulatory

Preclinical

6.4. By deal type

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Joint venture

Licensing

Manufacturing

Marketing

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

6.5. By therapy area

Cardiovascular

Central Nervous System

Dermatology

Gastrointestinal

Genetic disorders

Genitourinary

Gynaecology

Hematology

Hospital care

Infectives

Metabolic

Musculoskeletal

Obstetrics

Oncology

Ophthalmics

Pediatrics

Schizophrenia

Respiratory

 

Chapter 7 – Diagnostics dealmaking by technology type 

 

7.1. Introduction

7.2. Deals by diagnostics type

Diagnostics

Chapter 8 – Diagnostic partnering resource center

8.1. Diagnostic partnering events

8.2. Further reading on diagnostic dealmaking

Recent report titles from Current Partnering

Order Form – Subscription Access Products

 

Table of figures 

 

Figure 1: Diagnostic partnering since 2009             

Figure 2: Most active diagnostic dealmakers 2009-2014    

Figure 3: Big pharma – top 50 – diagnostic deals 2009 to 2014       

Figure 4: Big pharma diagnostic deal frequency – 2009 to 2014      

Figure 5: Big biotech – top 50 – diagnostic deals 2009 to 2014       

Figure 6: Big biotech diagnostic deal frequency – 2009 to 2014      

Figure 7: Diagnostics partnering by deal type since 2009   

Figure 8: Diagnostics partnering by stage of development since 2009          

Figure 9: Diagnostics partnering by disease type since 2009            

Figure 10: Diagnostics partnering by oncology target since 2009   

Figure 11: Diagnostics partnering by diagnostics type since 2009   

Figure 12: Diagnostic deals with a headline value – by stage of development           

Figure 13: Diagnostic deal headline value distribution – discovery stage, US$million              

Figure 14: Diagnostic deal headline value distribution – preclinical stage, US$million - detail              

Figure 15: Diagnostic deal headline value distribution – phase I stage, US$million   

Figure 16: Diagnostic deal headline value distribution – phase II stage, US$million  

Figure 17: Diagnostic deal headline value distribution – phase III stage, US$million 

Figure 18: Diagnostic deal headline value distribution –regulatory stage, US$million             

Figure 19: Diagnostic deal headline value distribution – marketed stage, US$million              

Figure 20: Summary median headline value by stage of development, 2009-2014   

Figure 21: Diagnostic deals with upfront payment values – by stage of development             

Figure 22: Diagnostic deal upfront payment distribution – discovery stage, US$million         

Figure 23: Diagnostic deal upfront payment distribution – preclinical stage, US$million        

Figure 24: Diagnostic deal upfront payment distribution – phase I stage, US$million              

Figure 25: Diagnostic deal upfront payment distribution – phase II stage, US$million            

Figure 26: Diagnostic deal upfront payment distribution – phase III stage, US$million           

Figure 27: Diagnostic deal upfront payment distribution – regulatory stage, US$million        

Figure 28: Diagnostic deal upfront payment distribution – marketed stage, US$million         

Figure 29: Summary median upfront value by stage of development, 2009-2014     

Figure 30: Diagnostic deals with milestone payment values – by stage of development        

Figure 31: Diagnostic deal milestone payment distribution – discovery stage, US$million     

Figure 32: Diagnostic deal milestone payment distribution – preclinical stage, US$million    

Figure 33: Diagnostic deal milestone payment distribution – phase I stage, US$million         

Figure 34: Diagnostic deal milestone payment distribution – phase II stage, US$million        

Figure 35: Diagnostic deal milestone payment distribution – phase III stage, US$million       

Figure 36: Diagnostic deal milestone payment distribution – regulatory stage, US$million   

Figure 37: Diagnostic deal milestone payment distribution – marketed stage, US$million     

Figure 38: Diagnostic deals with royalty rates       

Figure 39: Diagnostic deal rolyalty rate payment distribution – discovery stage, US$million 

Figure 40: Diagnostic deal royalty rate payment distribution – preclinical stage, US$million 

Figure 41: Diagnostic deal royalty rate payment distribution – phase I stage, US$million      

Figure 42: Diagnostic deal royalty rate payment distribution – phase II stage, US$million     

Figure 43: Diagnostic deal royalty rate payment distribution – phase III stage, US$million    

Figure 44: Diagnostic deal royalty rate payment distribution – regulatory stage, US$million

Figure 45: Diagnostic deal royalty rate payment distribution – marketed stage, US$million  

Figure 46: Summary median %royalty value by stage of development, 2009-2014   

Figure 47: Components of the typical diagnostic deal structure      

Figure 48: Top diagnostic deals by value since 2009            

Figure 49: Top diagnostic deals signed by big pharma value since 2009       

Figure 50: Forthcoming partnering events